Monday, 27 January 2014
Tuesday, 26 November 2013
ViiV Healthcare, the HIV company established by GlaxoSmithKline and Pfizer in 2009, announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA has recommended marketing authorization for Tivicay (dolutegravir) for use in combination with other antiretroviral medicinal products for the treatment of HIV-infected patients. How soon could the drug be approved in the EU? Find out...